Fundamentals of Pharmaceutical Nanoscience
暫譯: 藥物奈米科學基礎
Uchegbu, Ijeoma F., Schätzlein, Andreas G., Lalatsa, Aikaterini
商品描述
Nanoscience or the science of the very small offers the pharmaceutical scientist a wealth of opportunities. By fabricating at the nanoscale, it is possible to exert unprecedented control on drug activity. This textbook will showcase a variety of nanosystems working from their design and construction to their application in the field of drug delivery. The book is intended for graduate students in drug delivery, physical and polymer chemistry, and applied pharmaceutical sciences courses that involve fundamental nanoscience.
The purpose of the text is to present physicochemical and biomedical properties of synthetic polymers with an emphasis on their application in polymer therapeutics i.e., pharmaceutical nanosystems, drug delivery and biological performance. There are two main objectives of this text. The first is to provide advanced graduate students with knowledge of the principles of nanosystems and polymer science including synthesis, structure, and characterization of solution and solid state properties. The second is to describe the fundamentals of therapeutic applications of polymers in drug delivery, targeting, response modifiers as well as regulatory issues.
The courses, often listed as Advanced Drug Delivery and Applied Pharmaceutics; Polymer Therapeutics; or Nanomedicine, are designed as an overview of the field specifically for graduate students in the Department of Pharmaceutical Sciences Graduate Programs. However, the course content may also be of interest for graduate students in related biomedical research programs.
These courses generally include a discussion of the major principles of polymer science and fundamental concepts of application of polymers as modern therapeutics. All courses are moving away from the above mentioned course names and going by 'pharmaceutical nanoscience or nanosystems'. This area of research and technology development has attracted tremendous attention during the last twodecades and it is expected that it will continue to grow in importance. However, the area is just emerging and courses are limited but they are offered.
商品描述(中文翻譯)
奈米科學或極小尺度的科學為藥物科學家提供了豐富的機會。透過在奈米尺度上進行製造，可以對藥物活性施加前所未有的控制。本教科書將展示各種奈米系統，涵蓋其設計、建構到在藥物傳遞領域的應用。該書旨在為研究藥物傳遞、物理與聚合物化學以及應用藥物科學課程的研究生提供基礎奈米科學的知識。
本書的目的是介紹合成聚合物的物理化學和生物醫學特性，重點在於其在聚合物治療學中的應用，即藥物奈米系統、藥物傳遞和生物性能。本書有兩個主要目標。第一個是為高級研究生提供奈米系統和聚合物科學的原理知識，包括合成、結構和溶液及固態特性的表徵。第二個是描述聚合物在藥物傳遞、靶向、反應修飾劑以及監管問題中的治療應用基礎。
這些課程通常被列為高級藥物傳遞和應用藥劑學；聚合物治療學；或奈米醫學，旨在為藥物科學研究生提供該領域的概述。然而，課程內容對於相關生物醫學研究計劃的研究生也可能具有吸引力。
這些課程通常包括聚合物科學的主要原則和聚合物作為現代治療學應用的基本概念的討論。所有課程都逐漸從上述課程名稱轉向「藥物奈米科學或奈米系統」。這一研究和技術開發領域在過去二十年中引起了極大的關注，預計其重要性將持續增長。然而，該領域仍在新興階段，課程數量有限，但仍然提供。
作者簡介
Professor Ijeoma F. Uchegbu
Ijeoma Uchegbu FMedSci is UCL's Professor of Pharmaceutical Nanoscience, a fellow of the Academy of Medical Sciences, an honorary fellow of the Royal Society of Chemistry, a governor on the Wellcome board (one of the largest biomedical sciences research charities in the world), a member of the Academy of Medical Sciences Council and Chief Scientific Officer of Nanomerics Ltd. In 2024, Uchegbu will take up the position of President of Wolfson College, University of Cambridge having been elected to the position in 2023. Uchegbu has served as Chair of the Academy of Pharmaceutical Sciences and chaired the UK's Engineering and Physical Sciences Research Council and Science Foundation Ireland grant prioritisation panels.
Uchegbu has studied the mechanisms of drug transport across biological barriers and created transformational drug transport nanoparticles. She was the first to show that peptides could be delivered across the blood brain barrier to elicit a pharmacological response, when presented as peptide drug nanofibers and the first to demonstrate, via definitive pharmacology and pharmacokinetics evidence, peptide transport into the brain, using peptide nanoparticles delivered via the nose to brain route. These findings led to the development of the enkephalin pain medicine candidate Envelta(TM), which was designed to address the opioid crisis. In preclinical studies, Envelta(TM) showed no analgesic tolerance, reward seeking behaviour or potential to cause significant constipation. Envelta has been out licensed for clinical development.
The technology underpinning Envelta(TM) won first prize in the Royal Society of Chemistry's Emerging Technologies competition in 2017 and the Academy of Pharmaceutical Sciences Science Innovation Award in 2016. Three other medicine candidates based on this nanotechnology have further been out-licensed to pharmaceutical companies.
Uchegbu has also won numerous prizes for her work and these include: the UK Government's Women of Outstanding Achievement in Science, Engineering and Technology 2007, Royal Pharmaceutical Society Pharmaceutical Scientist of the Year 2012, Special Recognition Business of Science Leadership Award 2023 and others.
Uchegbu's scientific research work has been funded continuously for over two decades by the UK's Engineering and Physical Sciences Research Council and she serves on the Biotechnology and Biological Sciences Research Council's governing body.
Dr Andreas G. Schatzlein
Andreas Schatzlein has a track record of medicines development and translational research in industry and academia. His research interests focus on the discovery and preclinical/clinical development of targeted anti-cancer drugs and nanomedicines and the understanding of their underlying biology. Andreas is a veterinary surgeon by training and, after completion of his doctorate on transdermal nanomedicines delivery, joined the biotech start-up IDEA in Munich to develop this technology commercially.
In 1996 joined academia at the Cancer Research UK Beatson Laboratories at the University of Glasgow where became leader of the Experimental Therapeutics and Gene Medicines Group. There he was also responsible for setting up a unit that carried out analysis of pharmacokinetics and pharmacodynamics readouts from early phase translational oncology/nanomedicines trials using a good clinical laboratory practice framework. He currently is a Reader at the UCL School of Pharmacy and co-founder and CEO of Nanomerics Ltd, a UCL spinout company developing pharmaceutical nanotechnology.
Dr Aikaterini Lalatsa
Aikaterini Lalatsa is a Reader in Nanomedicines and the Deputy Director of Cancer Research UK (CRUK) Formulation Unit (a MHRA licensed manufacturing unit for sterile and oral new Investigational Medicinal Products for Phase I/II clinical trials) at Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde. Katerina has a track record in development and translation of biologics, chemotherapeutics and nanomedicines working closely with industry towards translation into first in human studies. She leads the Bio-engineering, Biomaterials and Nanomedicine (BioN) laboratory (originally at University of Portsmouth and now at Strathclyde) that attracted funding from national and international government, charity or industrial sources. She is the inventor of 4 international patents and her work has led to a paradigm shift in the non-invasive delivery of peptides, proteins and antibodies and chemotherapeutics across the blood-brain barrier. Katerina is the MSc in Pharmaceutical Quality and Good Manufacturing Practise course leader at University of Strathclyde.
Porf. Dolores R. Serrano
Dolores received an European PhD with CUM LAUDE in 2013. After completing her doctorate studies, she worked as a postdoctoral Fellow at the School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin (Ireland) as part of SSPC consortium (Synthesis and Solid State Pharmaceutical Center). She was appointed as a lecturer in the Complutense University of Madrid in October 2015, and recently was promoted to Professor in 2023. She is the co-inventor of three patents and coauthor in over 80 publications. She received several scientific awards such as the Cantabria Labs Innovation Award in Dermatology in 2022, the Roche Institute Award in Digital Health in 2020, and the Research Pharmacy Award "Mario Martin Velamazan" in 2018. She has created one of the first 3D printing laboratory at the School of Pharmacy in Complutense University, being a referent on 3D printing of medicines. Her research team has also a consolidated background in 3D printing of microfluidic chips, especially for the manufacturing of nanomedicines, such as liposomes and nanoparticles.
作者簡介(中文翻譯)
伊傑歐瑪·F·烏切古布教授
伊傑歐瑪·烏切古布（Ijeoma Uchegbu FMedSci）是倫敦大學學院（UCL）藥物奈米科學的教授，英國醫學科學院的院士，皇家化學學會的榮譽院士，威康基金會（Wellcome）董事會的成員（這是全球最大的生物醫學科學研究慈善機構之一），以及醫學科學院理事會的成員和Nanomerics Ltd.的首席科學官。烏切古布在2024年將擔任劍橋大學沃爾夫森學院的院長，該職位於2023年當選。她曾擔任藥物科學學院的主席，並主持英國工程與物理科學研究委員會及愛爾蘭科學基金會的資助優先小組。
烏切古布研究了藥物穿越生物屏障的機制，並創造了變革性的藥物運輸奈米顆粒。她是第一位展示肽類可以作為肽藥物奈米纖維穿越血腦屏障以引發藥理反應的研究者，也是第一位通過確定的藥理學和藥代動力學證據證明肽類能夠進入大腦的研究者，使用通過鼻腔到大腦路徑傳遞的肽奈米顆粒。這些發現促成了恩克法林（enkephalin）止痛藥候選藥物Envelta(TM)的開發，旨在應對鴉片類藥物危機。在臨床前研究中，Envelta(TM)顯示出沒有止痛耐受性、尋求獎勵行為或造成顯著便秘的潛力。Envelta已被授權進行臨床開發。
支撐Envelta(TM)的技術在2017年贏得了皇家化學學會新興技術競賽的第一名，並在2016年獲得藥物科學學院的科學創新獎。基於這項奈米技術的另外三個藥物候選者也已被授權給製藥公司。
烏切古布因其工作獲得了多項獎項，包括：2007年英國政府的傑出女性科學、工程和技術成就獎，2012年皇家藥學會年度藥物科學家獎，2023年科學領導獎特別表彰等。
烏切古布的科學研究工作已連續二十多年獲得英國工程與物理科學研究委員會的資助，她還在生物技術和生物科學研究委員會的管理機構中任職。
安德烈亞斯·G·沙茨萊因博士
安德烈亞斯·沙茨萊因在產業和學術界擁有藥物開發和轉化研究的豐富經驗。他的研究興趣集中在靶向抗癌藥物和奈米藥物的發現及臨床前/臨床開發，以及理解其基礎生物學。安德烈亞斯是一名受過訓練的獸醫，完成了關於經皮奈米藥物傳遞的博士學位後，加入了位於慕尼黑的生技初創公司IDEA，商業化這項技術。
1996年，他加入格拉斯哥大學的英國癌症研究中心Beatson實驗室，成為實驗治療學和基因藥物小組的負責人。在那裡，他還負責設立一個單位，使用良好臨床實驗室實踐框架進行早期階段轉化腫瘤學/奈米藥物試驗的藥代動力學和藥效學數據分析。他目前是倫敦大學學院藥學院的讀者，並且是Nanomerics Ltd.的共同創辦人和首席執行官，該公司專注於藥物奈米技術的開發。
艾卡特琳娜·拉拉察博士
艾卡特琳娜·拉拉察是奈米藥物的讀者，並擔任斯特拉斯克萊德大學（University of Strathclyde）藥學與生物醫學科學研究所（SIPBS）癌症研究英國（CRUK）配方單位的副主任（該單位是MHRA認證的無菌和口服新研究藥物的製造單位，專為I/II期臨床試驗服務）。Katerina在生物製劑、化療藥物和奈米藥物的開發和轉化方面有著良好的記錄，並與產業密切合作，推進人類首次研究的轉化。她領導生物工程、生物材料和奈米藥物（BioN）實驗室（最初位於朴茨茅斯大學，現在位於斯特拉斯克萊德），該實驗室吸引了來自國內外政府、慈善機構或工業來源的資金。她是四項國際專利的發明人，其工作促成了在非侵入性傳遞肽類、蛋白質、抗體和化療藥物穿越血腦屏障方面的範式轉變。Katerina是斯特拉斯克萊德大學藥物質量和良好製造實踐碩士課程的負責人。
多洛雷斯·R·塞拉諾教授
多洛雷斯於2013年獲得歐洲博士學位，並以優異成績畢業。完成博士學位後，她在都柏林三一學院的藥學與藥物科學學院擔任博士後研究員，並作為SSPC聯盟（合成與固態藥物中心）的一部分。她於2015年10月被任命為馬德里康普頓斯大學的講師，並於2023年晉升為教授。她是三項專利的共同發明人，並在80多篇出版物中擔任共同作者。她獲得了多項科學獎項，包括2022年坎塔布里亞實驗室皮膚科創新獎、2020年羅氏研究所數位健康獎和2018年“馬里奧·馬丁·維拉馬贊”研究藥學獎。她在康普頓斯大學的藥學院創建了第一個3D列印實驗室之一，成為藥物3D列印的參考。她的研究團隊在微流體晶片的3D列印方面也有穩固的背景，特別是在奈米藥物（如脂質體和奈米顆粒）的製造方面。
